Next report date
Report period
H1 2024
EPS estimate
−0.40HKD
Revenue estimate
—
−0.71HKD
−476.90 MHKD
21.06 MHKD
456.78 M
About ABBISKO CAYMAN LTD
Sector
CEO
Yao Chang Xu
Headquarters
Shanghai
Website
Employees (FY)
258
Founded
2016
FIGI
BBG012R769D9
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The firm designed and developed a pipeline of fourteen candidates focused on oncology, including six candidates at clinical stage. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company was founded by Yao Chang Xu, Hong Ping Yu, and Zhui Chen on April 12, 2016 and is headquartered in Shanghai, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2256 is 3.31 HKD — it has increased by 0.91% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange ABBISKO CAYMAN LTD stocks are traded under the ticker 2256.
ABBISKO CAYMAN LTD is going to release the next earnings report on Aug 19, 2024. Keep track of upcoming events with our Earnings Calendar.
2256 stock is 2.46% volatile and has beta coefficient of 1.00. Check out the list of the most volatile stocks — is ABBISKO CAYMAN LTD there?
2256 earnings for the last quarter are −0.35 HKD per share, whereas the estimation was −0.59 HKD resulting in a 41.82% surprise. The estimated earnings for the next quarter are −0.57 HKD per share. See more details about ABBISKO CAYMAN LTD earnings.
Yes, you can track ABBISKO CAYMAN LTD financials in yearly and quarterly reports right on TradingView.
2256 stock has risen by 11.82% compared to the previous week, the month change is a 16.55% rise, over the last year ABBISKO CAYMAN LTD has showed a 14.53% increase.
2256 net income for the last quarter is −240.91 M HKD, while the quarter before that showed −235.91 M HKD of net income which accounts for −2.12% change. Track more ABBISKO CAYMAN LTD financial stats to get the full picture.
Today ABBISKO CAYMAN LTD has the market capitalization of 2.28 B, it has decreased by 3.83% over the last week.
No, 2256 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2256 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBISKO CAYMAN LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 258.00 employees. See our rating of the largest employees — is ABBISKO CAYMAN LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBISKO CAYMAN LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBISKO CAYMAN LTD stock shows the buy signal. See more of ABBISKO CAYMAN LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ABBISKO CAYMAN LTD future price: according to them, 2256 price has a max estimate of 15.92 HKD and a min estimate of 3.59 HKD. Read a more detailed ABBISKO CAYMAN LTD forecast: see what analysts think of ABBISKO CAYMAN LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBISKO CAYMAN LTD EBITDA is −543.48 M HKD, and current EBITDA margin is −2.58 K%. See more stats in ABBISKO CAYMAN LTD financial statements.